Do analysts prefer BBLG or QNRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, BBLG or QNRX?

Bone Biologics is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bone Biologics N/A N/A -$3.11M -$2.27 N/A Quoin Pharmaceuticals N/A N/A -$15.81M -$29.56 N/A

Is BBLG or QNRX more profitable?

Bone Biologics' return on equity of -50.47% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -50.47% -47.40% Quoin Pharmaceuticals N/A -489.85% -221.29%

Do analysts rate BBLG or TNON?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tenon Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate NVNO or BBLG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, NVNO or BBLG?

Bone Biologics is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enVVeno Medical N/A N/A -$19.47M -$25.54 N/A Bone Biologics N/A N/A -$3.11M -$2.27 N/A

Is NVNO or BBLG more profitable?

Bone Biologics' return on equity of -50.47% beat enVVeno Medical's return on equity. Company Net Margins Return on Equity Return on Assets enVVeno Medical N/A -66.39% -60.42% Bone Biologics N/A -50.47% -47.40%

Do analysts prefer HSCS or BBLG?

HeartSciences presently has a consensus price target of $8.00, suggesting a potential upside of 325.53%. Given HeartSciences' stronger consensus rating and higher possible upside, research analysts clearly believe HeartSciences is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, HSCS or BBLG?

Bone Biologics is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HeartSciences N/A N/A -$8.77M -$4.94 N/A Bone Biologics N/A N/A -$3.11M -$2.27 N/A

Is HSCS or BBLG more profitable?

Bone Biologics' return on equity of -50.47% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -333.50% -140.18% Bone Biologics N/A -50.47% -47.40%

Do analysts recommend BBLG or NDRA?

ENDRA Life Sciences has a consensus target price of $25.00, indicating a potential upside of 496.66%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe ENDRA Life Sciences is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, BBLG or NDRA?

Bone Biologics is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bone Biologics N/A N/A -$3.11M -$2.27 N/A ENDRA Life Sciences N/A N/A -$7.03M -$8.15 N/A

Is BBLG or NDRA more profitable?

Bone Biologics' return on equity of -50.47% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -50.47% -47.40% ENDRA Life Sciences N/A -433.64% -204.58%

Bone Biologics (BBLG) Competitors

$1.24 +0.01 (+0.81%)

Closing price 06/10/2026 03:59 PM Eastern

Extended Trading

$1.23 -0.01 (-0.81%)

As of 06/10/2026 07:31 PM Eastern

Compare

BBLG vs. QNRX, TNON, NVNO, HSCS, and NDRA

Should you buy Bone Biologics stock or one of its competitors? MarketBeat compares Bone Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bone Biologics include Quoin Pharmaceuticals (QNRX), Tenon Medical (TNON), enVVeno Medical (NVNO), HeartSciences (HSCS), and ENDRA Life Sciences (NDRA). These companies are all part of the "medical equipment" industry.

How does Bone Biologics compare to Quoin Pharmaceuticals?

Bone Biologics (NASDAQ:BBLG) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 6.1% of Bone Biologics shares are held by company insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bone Biologics is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than Bone Biologics. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 2 mentions for Bone Biologics. Quoin Pharmaceuticals' average media sentiment score of 0.72 beat Bone Biologics' score of 0.43 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Bone Biologics	Neutral
Quoin Pharmaceuticals	Positive

Bone Biologics' return on equity of -50.47% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

Bone Biologics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market.

Summary

Bone Biologics and Quoin Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does Bone Biologics compare to Tenon Medical?

Bone Biologics (NASDAQ:BBLG) and Tenon Medical (NASDAQ:TNON) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tenon Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bone Biologics has higher earnings, but lower revenue than Tenon Medical. Bone Biologics is trading at a lower price-to-earnings ratio than Tenon Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A
Tenon Medical	$3.94M	1.75	-$12.56M	-$1.29	N/A

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 22.7% of Tenon Medical shares are owned by institutional investors. 6.1% of Bone Biologics shares are owned by company insiders. Comparatively, 0.3% of Tenon Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Bone Biologics had 1 more articles in the media than Tenon Medical. MarketBeat recorded 2 mentions for Bone Biologics and 1 mentions for Tenon Medical. Tenon Medical's average media sentiment score of 0.94 beat Bone Biologics' score of 0.43 indicating that Tenon Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Bone Biologics	Neutral
Tenon Medical	Positive

Bone Biologics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Tenon Medical has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Bone Biologics has a net margin of 0.00% compared to Tenon Medical's net margin of -270.09%. Bone Biologics' return on equity of -50.47% beat Tenon Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
Tenon Medical	-270.09%	-907.60%	-110.17%

Summary

Bone Biologics and Tenon Medical tied by winning 7 of the 14 factors compared between the two stocks.

How does Bone Biologics compare to enVVeno Medical?

enVVeno Medical (NASDAQ:NVNO) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

Bone Biologics is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47M	-$25.54	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

In the previous week, enVVeno Medical and enVVeno Medical both had 2 articles in the media. enVVeno Medical's average media sentiment score of 1.46 beat Bone Biologics' score of 0.43 indicating that enVVeno Medical is being referred to more favorably in the media.

Company	Overall Sentiment
enVVeno Medical	Positive
Bone Biologics	Neutral

Bone Biologics' return on equity of -50.47% beat enVVeno Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-66.39%	-60.42%
Bone Biologics	N/A	-50.47%	-47.40%

enVVeno Medical has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

34.7% of enVVeno Medical shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 15.0% of enVVeno Medical shares are held by insiders. Comparatively, 6.1% of Bone Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

enVVeno Medical beats Bone Biologics on 6 of the 10 factors compared between the two stocks.

How does Bone Biologics compare to HeartSciences?

HeartSciences (NASDAQ:HSCS) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Bone Biologics is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$8.77M	-$4.94	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

Bone Biologics' return on equity of -50.47% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-333.50%	-140.18%
Bone Biologics	N/A	-50.47%	-47.40%

HeartSciences presently has a consensus price target of $8.00, suggesting a potential upside of 325.53%. Given HeartSciences' stronger consensus rating and higher possible upside, research analysts clearly believe HeartSciences is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 4.9% of HeartSciences shares are held by company insiders. Comparatively, 6.1% of Bone Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

HeartSciences has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

In the previous week, HeartSciences and HeartSciences both had 2 articles in the media. HeartSciences' average media sentiment score of 0.93 beat Bone Biologics' score of 0.43 indicating that HeartSciences is being referred to more favorably in the media.

Company	Overall Sentiment
HeartSciences	Positive
Bone Biologics	Neutral

Summary

HeartSciences and Bone Biologics tied by winning 6 of the 12 factors compared between the two stocks.

How does Bone Biologics compare to ENDRA Life Sciences?

Bone Biologics (NASDAQ:BBLG) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 6.1% of Bone Biologics shares are held by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bone Biologics is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A

ENDRA Life Sciences has a consensus target price of $25.00, indicating a potential upside of 496.66%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe ENDRA Life Sciences is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bone Biologics' return on equity of -50.47% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
ENDRA Life Sciences	N/A	-433.64%	-204.58%

Bone Biologics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

In the previous week, ENDRA Life Sciences had 9 more articles in the media than Bone Biologics. MarketBeat recorded 11 mentions for ENDRA Life Sciences and 2 mentions for Bone Biologics. ENDRA Life Sciences' average media sentiment score of 1.08 beat Bone Biologics' score of 0.43 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Bone Biologics	Neutral
ENDRA Life Sciences	Positive

Summary

ENDRA Life Sciences beats Bone Biologics on 7 of the 13 factors compared between the two stocks.

Get Bone Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBLG vs. The Competition

Export

Metric	Bone Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.21M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	-0.55	18.83	24.65	23.63
Price / Sales	N/A	298.86	503.21	104.15
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	0.41	8.00	10.43	6.70
Net Income	-$3.11M	$23.89M	$3.56B	$337.26M
7 Day Performance	-1.51%	-5.43%	-2.94%	-2.43%
1 Month Performance	-6.49%	-4.18%	-0.39%	0.19%
1 Year Performance	-74.75%	36.70%	20.10%	23.15%

Bone Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBLG Bone Biologics	0.8232 of 5 stars	$1.24 +0.8%	N/A	-77.7%	$2.21M	N/A	N/A	2	Short Interest Increase
QNRX Quoin Pharmaceuticals	1.1373 of 5 stars	$4.29 -3.2%	N/A	-39.2%	$8.62M	N/A	N/A	4	Short Interest Decrease
TNON Tenon Medical	1.2994 of 5 stars	$0.64 +0.8%	N/A	-40.3%	$7.35M	$3.94M	N/A	8
NVNO enVVeno Medical	1.1209 of 5 stars	$10.75 +0.4%	N/A	-93.2%	$7.20M	N/A	N/A	30
HSCS HeartSciences	2.9804 of 5 stars	$2.01 -1.5%	$8.00 +298.0%	-47.6%	$6.39M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBLG) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bone Biologics (BBLG) Competitors

BBLG vs. QNRX, TNON, NVNO, HSCS, and NDRA

How does Bone Biologics compare to Quoin Pharmaceuticals?

Summary

How does Bone Biologics compare to Tenon Medical?

Summary

How does Bone Biologics compare to enVVeno Medical?

Summary

How does Bone Biologics compare to HeartSciences?

Summary

How does Bone Biologics compare to ENDRA Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBLG vs. The Competition

Bone Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bone Biologics (BBLG) Competitors

BBLG vs. QNRX, TNON, NVNO, HSCS, and NDRA

How does Bone Biologics compare to Quoin Pharmaceuticals?

Do institutionals & insiders hold more shares of BBLG or QNRX?

Do analysts prefer BBLG or QNRX?

Which has better earnings & valuation, BBLG or QNRX?

Does the media refer more to BBLG or QNRX?

Is BBLG or QNRX more profitable?

Which has more risk & volatility, BBLG or QNRX?

Summary

How does Bone Biologics compare to Tenon Medical?

Do analysts rate BBLG or TNON?

Which has better valuation and earnings, BBLG or TNON?

Do institutionals and insiders have more ownership in BBLG or TNON?

Does the media refer more to BBLG or TNON?

Which has more risk & volatility, BBLG or TNON?

Is BBLG or TNON more profitable?

Summary

How does Bone Biologics compare to enVVeno Medical?

Which has better valuation and earnings, NVNO or BBLG?

Does the media favor NVNO or BBLG?

Is NVNO or BBLG more profitable?

Which has more volatility & risk, NVNO or BBLG?

Do analysts rate NVNO or BBLG?

Do institutionals & insiders have more ownership in NVNO or BBLG?

Summary

How does Bone Biologics compare to HeartSciences?

Which has preferable earnings and valuation, HSCS or BBLG?

Is HSCS or BBLG more profitable?

Do analysts prefer HSCS or BBLG?

Do institutionals & insiders hold more shares of HSCS or BBLG?

Which has more volatility and risk, HSCS or BBLG?

Does the media favor HSCS or BBLG?

Summary

How does Bone Biologics compare to ENDRA Life Sciences?

Do institutionals & insiders have more ownership in BBLG or NDRA?

Which has higher valuation & earnings, BBLG or NDRA?

Do analysts recommend BBLG or NDRA?

Is BBLG or NDRA more profitable?

Which has more risk & volatility, BBLG or NDRA?

Does the media refer more to BBLG or NDRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBLG vs. The Competition

Bone Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools